Formula with a specific beta-lactoglobulin peptide

A method for:

• inducing of oral immune tolerance against milk protein;
• and/or
• preventing or treating of oral immune intolerance against milk protein;
• and/or
• reducing the risk of developing oral immune intolerance against milk protein;
• and/or
• improving or enhancing of oral immune tolerance against milk protein,
• in a human subject, comprising administration to the subject a nutritional composition comprising a protein hydrolysate from mammalian milk, preferably milk from a species of the genus Bos, Bison, Bubalus or Capra, wherein the protein hydrolysate comprises at least one of the peptides having a sequence selected from the group consisting of SEQ ID NO:
• 2, SEQ ID NO:
• 3, SEQ ID NO:
• 4 and SEQ ID NO:
• 5,
• and wherein the composition comprises at least one strain of a lactic acid-producing, probiotic bacterium, and wherein the composition comprises less than 6 μg allergenic beta-lactoglobulin per g of total protein.

A nutritional composition comprising:

• a. a strain of lactic acid-producing, probiotic bacterium belonging to the genus Bifidobacterium;
• b. a milk protein hydrolysate from a species of the genus Bos, Bison, Bubalus or Capra, wherein the milk protein hydrolysate comprises at least one of the peptides having a sequence selected from the group consisting of SEQ ID NO:
• 2, SEQ ID NO:
• 3, SEQ ID NO:
• 4 and SEQ ID NO:
• 5;
• c. less than 6 μg allergenic beta-lactoglobulin, per g of total protein,
• d. less than 10 wt % of peptides or proteins having a size of 5 kDa or above, based on total protein, and
• e. at least 50 wt %, preferably at least 95 wt % of hydrolysed whey protein based on total protein,
• f. optionally one or more non-digestible oligosaccharide(s) selected from the group consisting of fructooligosaccharide, non-digestible dextrin, galactooligosaccharide, xylooligosaccharide, arabino-oligosaccharide, arabinogalacto-oligosaccharide, gluco-oligosaccharide, glucomanno-oligosaccharide, galactomanno-oligosaccharide, mannan-oligosaccharide, chito-oligosaccharide, uronic acid oligosaccharide, sialyloligosaccharide, and fucooligosaccharide, and mixtures thereof, and
• g. optionally long-chain polyunsaturated fatty acids, preferably docosahexaenoic acid (DHA), more preferably at least 0.35 wt. % DHA based on total fatty acids.